Gerald Hogue
Chief Executive Officer at Viviphi Ltd.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Joe McCann | M | 47 |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | 5 years |
Neil Fleshner | M | 60 |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | 5 years |
Allan Silber | M | 75 |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | 5 years |
Margaret Gilmour | F | 64 |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | 4 years |
Jonathan Goodman | M | 56 |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | 4 years |
Ari Shomair | M | - |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | - |
Justyna Kelly | F | 39 |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | 3 years |
William Demers | M | 66 |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | 4 years |
Michael Gottlieb | M | 45 |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | 4 years |
Fredrick D. Ashbury | M | - |
Viviphi Ltd.
Viviphi Ltd. Packaged SoftwareTechnology Services Viviphi Ltd., also known as VieCure, is an artificial intelligence platform that has developed a proprietary informatics software platform in conjunction with a clinical inference engine and point-of-care decision support system in oncology. The company is based in Denver, CO. The platform combines the latest in clinical knowledge with patient data to assist clinicians in generating personalized treatment plans and better managing a patient’s treatment throughout diagnosis, cancer therapy, and ongoing follow-up care. The company was founded by Fredrick D. Ashbury, Gerald Hogue. Gerald Hogue has been the CEO since incorporation. | - |
Michael Thompson | M | - | 1 years | |
Philip Johnson | M | 59 | 1 years | |
Jessica Jensen | F | 44 |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | 4 years |
Gordon Brooks | M | - | 1 years | |
Michael Mentesana | M | - |
Viviphi Ltd.
Viviphi Ltd. Packaged SoftwareTechnology Services Viviphi Ltd., also known as VieCure, is an artificial intelligence platform that has developed a proprietary informatics software platform in conjunction with a clinical inference engine and point-of-care decision support system in oncology. The company is based in Denver, CO. The platform combines the latest in clinical knowledge with patient data to assist clinicians in generating personalized treatment plans and better managing a patient’s treatment throughout diagnosis, cancer therapy, and ongoing follow-up care. The company was founded by Fredrick D. Ashbury, Gerald Hogue. Gerald Hogue has been the CEO since incorporation. | 2 years |
Peggy Gilmour | F | - |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | - |
Gerry Hogue | M | - |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | - |
Andrea Jackson | F | 45 |
Viviphi Ltd.
Viviphi Ltd. Packaged SoftwareTechnology Services Viviphi Ltd., also known as VieCure, is an artificial intelligence platform that has developed a proprietary informatics software platform in conjunction with a clinical inference engine and point-of-care decision support system in oncology. The company is based in Denver, CO. The platform combines the latest in clinical knowledge with patient data to assist clinicians in generating personalized treatment plans and better managing a patient’s treatment throughout diagnosis, cancer therapy, and ongoing follow-up care. The company was founded by Fredrick D. Ashbury, Gerald Hogue. Gerald Hogue has been the CEO since incorporation. | - |
Howard M. Glase | M | - |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | - |
Brad Prechtl | M | - |
Viviphi Ltd.
Viviphi Ltd. Packaged SoftwareTechnology Services Viviphi Ltd., also known as VieCure, is an artificial intelligence platform that has developed a proprietary informatics software platform in conjunction with a clinical inference engine and point-of-care decision support system in oncology. The company is based in Denver, CO. The platform combines the latest in clinical knowledge with patient data to assist clinicians in generating personalized treatment plans and better managing a patient’s treatment throughout diagnosis, cancer therapy, and ongoing follow-up care. The company was founded by Fredrick D. Ashbury, Gerald Hogue. Gerald Hogue has been the CEO since incorporation. | 2 years |
Chris Anderson | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
David Lubner | M | 60 | 2 years | |
Rajesh K. Malik | M | 65 | 2 years | |
Yael Margolin | M | 70 | 2 years | |
Bridget Martell | M | 58 | - | |
Matthew Vincent | M | - | 1 years | |
Donna Husack | F | - | 3 years | |
Daniel Pearlstein | M | - | 2 years | |
Myra Rosario Herrle | M | - | 2 years | |
Robin Hallett | M | - | - | |
Sherin Al-Safadi | M | - | - | |
Chris Horvath | M | - | 1 years | |
Melita Sequeira | F | - | - |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 33 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Gerald Hogue
- Personal Network